Please ensure Javascript is enabled for purposes of website accessibility

Should You Sell Abbott Laboratories Stock?

By Prosper Junior Bakiny - Jun 2, 2020 at 2:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A Goldman Sachs analyst just downgraded the medical device and healthcare company's stock.

Shares of Abbott Laboratories (ABT) are up by 6.3% year to date, a better-than-average performance relative to the broader market that it owes in part to its involvement in the fight against COVID-19. The healthcare company successfully developed several diagnostic tests for the coronavirus, but even though it's currently a leader in this niche, at least one analyst thinks investors should dump its stock. 

Specifically, Goldman Sachs analyst Amit Hazan downgraded Abbott's stock from neutral to sell. And although he increased his price target for the stock from $79 to $84, that new target is still 10% below where Abbott is currently trading. Hazan asserts that investors "overreacted" to Abbott's opportunity within the COVID-19 testing niche, and that other companies such as Roche are in better positions in this space. Is he right? I don't think so, and here's why. 

Nurse holding a test tube with blood for coronavirus testing.

Image Source: Getty Images.

Why Abbott Laboratories is worth buying 

First, it is worth noting that Abbott's ID Now COVID-19 test is one of the fastest on the market, capable of giving a positive result in as little as five minutes. There was some trouble with the test -- in mid-May, the Food and Drug Administration issued a warning that it could be returning false-negative results. But Abbott seems to have cleared up this issue. The healthcare company recently issued interim data from a clinical study that appears to show that ID Now is highly reliable. Abbott has other tests on the market as well, and I expect the company will remain one of the leaders in COVID-19 testing. 

Second, the company's financial position is robust. To quote CFO Robert E. Funck Jr: "[O]ver the last couple of years, we have put a heavy emphasis on strong cash flow generation and rapid debt paydown following a period of strategic shaping. This focused effort has positioned us with healthy leverage ratios and only a modest amount of debt coming due over the next few years."

Lastly, Abbott is a Dividend Aristocrat, and with 48 consecutive years of payout increases under its belt, it's just two away from joining the even more rarefied ranks of the Dividend Kings. While the company's yield of 1.47% is low, investors can be confident that Abbott is unlikely to slash or suspend its payout amid this crisis (in contrast to the 68 other S&P 500 companies that already have done so this year). 

For all those reasons -- and given Abbott's strong position in the medical devices market -- I think the company is worth serious consideration, particularly for investors who are willing to ride out this crisis and hold onto its shares for a while. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
The Goldman Sachs Group, Inc. Stock Quote
The Goldman Sachs Group, Inc.
Roche Holding AG Stock Quote
Roche Holding AG

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.